Cargando…

Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort

OBJECTIVE: In the general population, the incidence of stroke is increased following other serious events and hospitalisation. We investigated the impact of serious adverse events on the risk of stroke in patients with rheumatoid arthritis (RA), taking risk factors and treatment into account. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meissner, Y, Richter, A, Manger, B, Tony, HP, Wilden, E, Listing, J, Zink, A, Strangfeld, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Annals of the Rheumatic Diseases 2017
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561376/ https://www.ncbi.nlm.nih.gov/pubmed/28483768 http://dx.doi.org/10.1136/annrheumdis-2017-211209

Ejemplares similares

Evaluation of the RABBIT Risk Score for serious infections
por: Zink, A, et al.
Publicado: (2014)

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
por: Richter, A, et al.
Publicado: (2016)

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
por: Listing, Joachim, et al.
Publicado: (2015)

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
por: Strangfeld, A, et al.
Publicado: (2017)

Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT
por: Gerhold, Kerstin, et al.
Publicado: (2015)

Incidence of facial nerve palsies stratified by DMARD treatment in patients with rheumatoid arthritis: data from the RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2020)

Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort
por: Baganz, Lisa, et al.
Publicado: (2017)

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
por: Strangfeld, Anja, et al.
Publicado: (2010)

Sustainability of Rituximab Therapy in Different Treatment Strategies: Results of a 3-Year Followup of a German Biologics Register
por: Richter, Adrian, et al.
Publicado: (2014)

Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis
por: Schäfer, Martin, et al.
Publicado: (2020)

Corrigendum to: Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis
por: Schäfer, Martin, et al.
Publicado: (2020)

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
por: Strangfeld, A, et al.
Publicado: (2011)

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2023)

Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis
por: Meissner, Yvette, et al.
Publicado: (2016)

Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases
por: Albrecht, Katinka, et al.
Publicado: (2016)

Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020
por: Albrecht, Katinka, et al.
Publicado: (2023)

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
por: Redeker, Imke, et al.
Publicado: (2022)

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
por: Mercer, Louise K, et al.
Publicado: (2017)

Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National Database
por: Thiele, Katja, et al.
Publicado: (2022)

Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT
por: Schäfer, Martin, et al.
Publicado: (2020)

Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
por: Mercer, Louise K, et al.
Publicado: (2017)

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register
por: Listing, Joachim, et al.
Publicado: (2006)

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
por: Dikranian, Ara, et al.
Publicado: (2021)

Neues aus dem RABBIT-Register
por: Meißner, Yvette, et al.
Publicado: (2021)

Evolution of cost structures in rheumatoid arthritis over the past decade
por: Huscher, Dörte, et al.
Publicado: (2015)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case–control study
por: Dixon, W G, et al.
Publicado: (2011)

Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment
por: Rech, Juergen, et al.
Publicado: (2016)

Placebo-Related Adverse Events in Rheumatoid Arthritis
por: Sharma, Ratna Shree, et al.
Publicado: (2022)

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
por: Salliot, C, et al.
Publicado: (2009)

Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
por: Li, Xue, et al.
Publicado: (2022)

Quality of life, sleep and rheumatoid arthritis (QUASAR): a protocol for a prospective UK mHealth study to investigate the relationship between sleep and quality of life in adults with rheumatoid arthritis
por: Druce, Katie L, et al.
Publicado: (2018)

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017
por: Lindner, Lisa, et al.
Publicado: (2020)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis
por: Dixon, William G, et al.
Publicado: (2012)

No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis
por: Baradat, Claire, et al.
Publicado: (2017)

A patient-reported questionnaire developed in a German early arthritis cohort to assess periodontitis in patients with rheumatoid arthritis
por: Callhoff, Johanna, et al.
Publicado: (2019)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013)

15017 Monoclonal antibody use in rheumatoid arthritis: an evaluation of medical expenditure
por: Kelly, Robert A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sj0sos9ql3hennigbce8p62kd8